Fresenius sells Fresenius Medical Care shares to raise capital
The company sold 7.8 million shares for €300 million to reduce debt and fund growth platforms under its transformation strategy.
See the latest news and media coverage for Fresenius. We track all announcements, press releases, and industry mentions in real time, all in one place.
Healthcare products and private hospital services group
fresenius.comLast updated
In short: Fresenius raised its full-year earnings guidance following strong quarterly growth in its hospital and pharmaceutical operations.
The company sold 7.8 million shares for €300 million to reduce debt and fund growth platforms under its transformation strategy.
Fitch affirmed Fresenius' BBB- rating and cited stronger business profile, improved credit metrics, and reduced leverage under #FutureFresenius.
This shift enhances shareholder dialogue and transparency. The conversion is automatic via custodian banks, requiring no action from investors. The first trading day as registered shares occurred today.
Core EPS grew 14% at constant currency to €0.83, with EBIT up 10% to €719 million; the company now expects 10-15% Core EPS growth for 2026, up from 5-10%.
However, the profit jump is partly based on special effects: The burden from the exit from Fresenius Vamed decreased from almost 700 million euros last year to around...
JP Morgan Chase & Co. has conducted a detailed analysis of the Fresenius SE stock. Here are the resulting findings.
Fresenius raises annual targets after strong quarter, while Rheinmetall, Qiagen, Heidelberg Materials and Zalando struggle with pressures.
FDA's August 2026 warning letter to Fresenius Kabi's Ogden, Utah plant exposes how sponsor oversight of CMOs fails long ...
Track Fresenius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Fresenius and other trending companies.